LIFE: Lifecare ASA Q4 2025 results

03 Mar 2026 07:00 CET

Bergen, Norway, 3 March 2026 - Lifecare ASA (LIFE), a clinical stage medical
sensor company developing the next generation Continuous Glucose Monitor
(CGM), today publishes its Q4 2025 financial report and operational update.

Highlights:

* System-level validation milestone achieved
* Manufacturing reproducibility established
* Longevity study validates biocompatibility and functional coherence
* Regulatory foundation strengthened
* Financing secured to support near-term operations

Q4 2025 marked a decisive transition for Lifecare - from validating a
technology concept to demonstrating reproducible, system-level execution of a
fully integrated implantable Continuous Glucose Monitoring (CGM) platform.

During the quarter, Lifecare confirmed in vivo operation of its fully
integrated, wireless dual-cavity implant manufactured under the updated
production protocol. For the first time, implants from a reproducible
production batch tracked glucose behaviour inside living tissue without
calibration, smoothing or post-processing. This milestone represents a clear
shift in risk profile: from feasibility validation to controlled execution and
optimisation.

The results from the ongoing longevity study demonstrate coherent signal
behaviour aligned with physiological glucose changes, confirm
biocompatibility, and validate the integrity of our complete implant
architecture in real biological conditions. Together with CE marking of the
electronics module and continued regulatory progress toward first-in-human
studies, these achievements materially strengthen the foundation of Lifecare's
platform.

From a strategic perspective, Lifecare has now demonstrated that its
proprietary osmotic sensing principle functions not only in laboratory and
proof-of-concept settings, but as a fully integrated, implantable and
reproducibly manufactured system. The remaining development work is focused on
optimisation, regulatory execution and commercial scale-up.

Financially, 2025 reflects continued investment in engineering, manufacturing
readiness and regulatory preparation. At year-end, the company operated under
a bridge financing structure pending completion of the rights issue in January
2026, which secured immediate operational continuity. Further development,
including initiation of the CE trial and progression toward human market
launch in 2027, remains dependent on additional capital. The warrant programs
in March and June 2026 represent important funding opportunities to support
this next phase.

Importantly, the technical progress achieved during Q4 and early 2026 has
strengthened external confidence in the platform. The combination of
reproducible manufacturing, in vivo validation, regulatory advancement and
intellectual property development has positioned Lifecare in a fundamentally
stronger strategic position than one year ago.

Lifecare now moves forward with clear priorities: progressing regulatory
approvals for first-in-human trials, further refining implant performance and
system stability, advancing the veterinary pathway, and securing the capital
required to execute on the commercial roadmap.

Q4 2025 represents more than continued development. It marks the point at
which Lifecare's implant platform has transitioned from validated concept to
operational system - actively building the foundation for long-term commercial
realisation.

Results presentation

CEO Joacim Holter and CFO Renete Kaarvik will present the results live on
webcast today at 10:00 CET.

To access the webcast Join the meeting here.
(https://teams.microsoft.com/dl/launcher/launcher.html?url=%2F_%23%2Fl%2Fmeetup-
join%2F19%3Ameeting_YjUzMGE0NjQtYjNkOC00YjAzLWE1MDUtMDgyOTZmZGQ0MDVm%40thread.v2
%2F0%3Fcontext%3D%257B%2522Tid%2522%253a%252210b30f00-1bbd-4041-9c4d-64749f4a704
1%2522%252c%2522Oid%2522%253a%25223758e62c-12e5-4419-a645-4b77ef5225be%2522%257D
%26anon%3Dtrue&type=meetup-join&deeplinkId=46dd610d-93e8-459d-9046-e3295194f26a&
directDl=true&msLaunch=true&enableMobilePage=true&suppressPrompt=true)

A recording of the webcast will be available on our website after the event.

About us
Lifecare ASA is a medical sensor company developing technology for sensing and
monitoring of various body analytes. Lifecare's focus is to bring the next
generation of Continuous Glucose Monitoring systems to market. Lifecare
enables osmotic pressure as sensing principle. Lifecare's sensor technology is
suitable for identifying and monitoring the occurrence of a wide range of
analytes and molecules in the human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information has been submitted pursuant to the Securities Trading Act §
5-12 and MAR Article 17. The information was submitted for publication,
through the agency of the contact persons set out above, at 2026-03-03 07:00
CET.

More information:
Access the news on Oslo Bors NewsWeb site

667316_Lifecare Q4 2025 Report.pdf
667316_Lifecare Q4 2025 Presentation.pdf